Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 8/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1534984 | 1.00 | EPHX1 (0.43) | EPHX1ACHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL7768778 | 0.94 | EPHX1 (0.53) | EPHX1ACHESMN1; SMN2NPC1RAB9A | |
| SCHEMBL10137321 | 0.90 | KDM4E (0.36) | EPHX1ACHEALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL4764642 | 0.89 | EPHX1 (0.42) | EPHX1ACHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL6201756 | 0.87 | EPHX1 (0.41) | EPHX1ACHEALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL7886184 | 0.87 | ACHE (0.38) | ACHE | |
| SCHEMBL10137333 | 0.85 | HRH3 (0.36) | EPHX1ACHE | |
| SCHEMBL12868563 | 0.85 | HRH3 (0.36) | EPHX1ACHEALDH1A1 | |
| SCHEMBL8300168 | 0.82 | ATM (0.41) | ALDH1A1SMN1; SMN2RAB9AMAPK1ATM | |
| SCHEMBL730749 | 0.81 | MEN1 (0.36) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883627-B1 | BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| US-8575113-B2 | BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2013-11-05 | — | — | US | disclosed |
| EP-2423187-A1 | PROCESS FOR PRODUCTION OF N-ALKOXYCARBONYL-tert-LEUCINES | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-7772177-B2 | BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| EP-1883627-A1 | BIR DOMAIN BINDING COMPOUNDS | Aegera Therapeutics Inc. (CA) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006122408-A9 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC (CA) | 2007-01-25 | — | — | WO | disclosed |
| US-20060264379-A1 | BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2006-11-23 | — | — | US | disclosed |
| WO-2006122408-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2006-11-23 | — | — | WO | disclosed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264379-A1 | BIR domain binding compounds | BIRC5, BIRC3, BIRC2 | EPHX1 4269/4885ACHE 4744/4885ALDH1A1 3348/4885 |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | EPHX1 4269/4885ACHE 4744/4885ALDH1A1 3348/4885 |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | EPHX1 791/4885ACHE 2057/4885ALDH1A1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.